A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

NCT03180710 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: BioChaperone® Combo 75/25 at 0.6 U/kg
DRUG: BioChaperone® Combo 75/25 at 0.8 U/kg
DRUG: BioChaperone® Combo 75/25 at 1.0 U/kg
DRUG: Humalog® Mix25 at 0.8 U/kg

Sponsor

Adocia